WEIGAO GROUP (01066): Shandong Weigao Orthopaedic Device (688161.SH) is expected to achieve a net profit attributable to shareholders of 200 million to 240 million yuan in 2024, an increase of 78.07% to 113.68% year-on-year.

WEIGAO GROUP (01066) announced that Shandong Weigao Orthopaedic Device (688161.SH) is expected to achieve a net profit attributable to shareholders of the listed company of 200 million to 240 million yuan in 2024, an increase of 78.07% to 113.68% year-on-year; it is expected that the non-net profit will be approximately 191 million to 231 million yuan, an increase of 77.02% to 114.09%. In 2024, the comprehensive implementation of the orthopedic consumables with volume procurement has entered a stable period, Shandong Weigao Orthopaedic Device actively implements the volume procurement policy, adjusts its business strategy, re-plans its product line, optimizes cost control, strengthens cooperation with medical institutions, and explores diversified market channels to maximize market share and customer coverage, and achieve performance growth. Shandong Weigao Orthopaedic Device continues to promote sales mode transformation, builds collaborative sales capabilities focusing on key procedures, continuously improves clinical service capabilities; implements a large customer strategy to increase customer loyalty and expand customer coverage; at the same time, continuously optimizes product structure, leads the change in clinical procedures, promotes product collaborative sales, enhances product gross margin and market share. Shandong Weigao Orthopaedic Device's new production lines and new markets are developing rapidly, new business lines such as artificial bones, sports medicine, and minimally invasive spine are steadily advancing, laying a solid foundation for the layout of new businesses; overseas product registration is fully initiated and implemented, gradually enhancing international brand influence through market academic promotion. Shandong Weigao Orthopaedic Device strengthens refined performance management, rationalizes the investment in market expenses, effectively reduces the sales expense ratio by optimizing marketing structure and personnel structure, channel integration, and refined management of market expenses. Reorganize channel inventory, systematically manage self-built warehouses, consignment warehouses, and third-party logistics platform inventory, improve supply chain response speed, and significantly increase product turnover efficiency. In 2025, Shandong Weigao Orthopaedic Device will continue to advance the development layout in the field of orthopedic innovation, increase R&D investment in key products, expand the solid foundation of orthopedic innovative product matrix through independent R&D and exogenous mergers and acquisitions; continuously improve the professional level of sales organizations, further enhance collaborative sales capabilities; accelerate overseas business expansion, simultaneously implement various strategies for overseas blank markets and strategic markets, enhance international brand influence, and increase market share.